Anjeso
(Meloxicam)ApprovedSmall molecule
Boehringer IngelheimMeloxicam injection is used to temporarily relieve moderate to severe pain. It belongs to a class of medications that work by reducing the body's production of pain-causing and inflammation-causing substances.[2] Anjeso is currently approved and in use across 24 indications[4].[1]
Anjeso is one of 540 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Approved.
24
Indications
65
Total Trials
3
Active Trials
539
Competitors
7
FDA Applications
NDA/BLA/ANDA regulatory filings
11
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 23 indications
Competition
Competitive Landscape
1135 competitors in Multiple Myeloma
#DrugCompanyPhaseTrials
1Anjeso
Boehringer IngelheimApproved
Ninlaro
TakedaPreclinical
Prolia
AmgenPreclinical
Eliquis
Bristol-Myers SquibbPreclinical
Nolvadex
AstraZenecaPreclinical
Oncovin
EEastern Cooperative Oncology Group
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Abecma
Bristol-Myers SquibbPreclinical
Oblimersen Sodium
NNational Cancer Institute (NCI)
Preclinical
Chemotherapy Drug
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Osteoarthritis7 trials
Show 4 more trials
Rheumatoid Arthritis6 trials
Show 3 more trials
Tics3 trials
Fasting Conditions3 trials
Arthritis2 trials
36 more indications
Pharyngitis2 trials
Labor2 trials
Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fed Condition
Completed·—·Phase 1·NCT01161147·28 enrolled
Bioequivalence Study of Meloxicam Tablets 15 mg of Dr.Reddy's Laboratories Limited Under Fasting Condition
Completed·—·Phase 1·NCT01161134·28 enrolled
Efficacy and Safety2 trials
Ankylosing Spondylitis2 trials
Bawei Shenqi Pill in the Treatment of Ankylosing Spondylitis
Unknown status·SShanghai University of Traditional Chinese Medicine·Phase 2/3·NCT04480359·80 enrolled
Dysmenorrhea2 trials
Rheumatic Disease1 trial
Low back pain1 trial
Tolerance1 trial
Pharmacokinetic and Tolerance Study of Meloxicam Eye Drops in Healthy Volunteers
Unknown status·—·Phase 1·NCT04322175·80 enrolled
Ankle Surgery1 trial
Platelet Aggregation1 trial
Brachytherapy1 trial
Biliary Atresia1 trial
Multiple Myeloma1 trial
A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma
Completed·—·Phase 2·NCT02078102·38 enrolled
Pain After Surgery1 trial
Abdominal Surgery1 trial
Premedication1 trial
Effectiveness of Premedication on the Success Rate of Inferior Alveolar Nerve Block
Completed·—·N/A·NCT05097768·250 enrolled
Prilocaine1 trial
Lidocaine-prilocaine Cream Versus Rectal Meloxicam on Relief of Post-episiotomy Pain
Completed·—·Phase 3·NCT03146000·190 enrolled
Adult1 trial
Neck pain1 trial
MPA1 trial
Ovulation1 trial
Regulatory
FDA Approval Timeline[5]
Apr 13, 2000
MOBIC
NDA NDA020938
Jun 1, 2004
MELOXICAM
NDA NDA021530
Oct 22, 2015
VIVLODEX
NDA NDA207233
Oct 19, 2018
QMIIZ ODT
NDA NDA211210
Feb 20, 2020
ANJESO
NDA NDA210583
Apr 22, 2025
QAMZOVA
NDA NDA217593
Jun 5, 2025
XIFYRM
NDA NDA218395
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Anjeso drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Meloxicam. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]FDA Orange Book — Patent and exclusivity data for Anjeso. U.S. Food & Drug Administration.
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Cyclooxygenase-2 Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company